Neurogene Inc. (NGNE)
NASDAQ: NGNE · IEX Real-Time Price · USD
44.00
+1.74 (4.12%)
Jul 22, 2024, 10:22 AM EDT - Market open
Neurogene Employees
Neurogene had 91 employees as of December 31, 2023. The number of employees increased by 9 or 10.98% compared to the previous year.
Employees
91
Change (1Y)
9
Growth (1Y)
10.98%
Revenue / Employee
n/a
Profits / Employee
-$428,945
Market Cap
571.13M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 91 | 9 | 10.98% |
| Dec 31, 2022 | 82 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Community Health Systems | 61,000 |
| Cross Country Healthcare | 13,131 |
| Canopy Growth | 1,029 |
| Quanterix | 441 |
| OmniAb | 106 |
| PureTech Health | 90 |
| Terns Pharmaceuticals | 66 |
| PepGen | 64 |
NGNE News
- 20 days ago - Neurogene to Participate in BMO Genetic Medicines Summit - Business Wire
- 21 days ago - Neurogene Announces Addition to Russell 3000® Index - Business Wire
- 4 weeks ago - Neurogene Announces First Patient Dosed in High-Dose Cohort of NGN-401 Gene Therapy Clinical Trial for Rett Syndrome - Business Wire
- 6 weeks ago - Neurogene to Participate in Upcoming Conferences - Business Wire
- 7 weeks ago - Neurogene Announces NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for START Pilot Program - Business Wire
- 2 months ago - Neurogene Reports First Quarter 2024 Financial Results and Highlights Recent Updates - Business Wire
- 2 months ago - Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual Meeting - Business Wire
- 3 months ago - Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting - Business Wire